EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema [Yahoo! Finance]
EyePoint, Inc. (EYPT)
Last eyepoint, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
EyePoint, Inc. – Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU ™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). DURAVYU is an investigational sustained delivery therapy delivering vorolanib, a selective tyrosine kinase inhibitor (TKI) that brings a novel, multi-mechanism of action inhibiting VEGF-mediated vascular permeability, PDGF, and IL-6 mediated inflammation to the potential treatment of DME. “Dosing of the first patients in our two pivotal DME trials represents a significant mile
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]Yahoo! Finance
- Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 3/4/26 - Miss
EYPT
Analyst Actions
- 3/4/26 - Chardan Capital
EYPT
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 4
- 3/4/26 - Form 8-K
- EYPT's page on the SEC website